medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-4-38(413)-5-8medalphabet-1332Research ArticleСтатьиНеалкогольная жировая болезнь печени и псориаз: случайное сочетание или закономерная взаимосвязь?Non-alcoholic fatty liver disease and psoriasis: random combination or regular relationship?АхмедовВ. А.AkhmedovV. A.

д. м. н, проф., зав. кафедрой медицинской реабилитации дополнительного профессионального образования

г. Омск

Omsk

МеликовТ. И.MelikovT. I.

ординатор кафедры

г. Омск

Omsk

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава РоссииРоссияOmsk State Medical UniversityRussian Federation201918012020438Практическая гастроэнтерология58Copyright © Ахмедов В.А., Меликов Т.И., 20202020Ахмедов В.А., Меликов Т.И.Akhmedov V.A., Melikov T.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1332

За последние 10 лет становится все более очевидным, что неалкогольная жировая болезнь печени (НАЖБП) является мультисистемным заболеванием, которая поражает множество органов и систем посредством метаболических и иммунологических нарушений. Недавние обсервационные исследования показали, что распространенность НАЖБП значительно выше у пациентов с псориазом (встречается у 50 % этих пациентов). Примечательно, что псориаз ассоциируется с НАЖБП даже после учета признаков метаболического синдрома и других потенциальных факторов, воздействующих на лечение. В некоторых исследованиях также было высказано предположение, что у пациентов с псориазом чаще встречаются более распространенные и активные формы НАЖБП, чем у лиц без псориаза. Применение лекарственной терапии пациентов с сочетанием НАЖБП и псориаза с включением препарата Легалон является патогенетически обоснованным.

Over the past 10 years, it has become increasingly evident that nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects multiple extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways. Recent observational studies have shown that the prevalence of NAFLD is remarkably higher in psoriatic patients (occurring in up to 50 % of these patients) than in matched control subjects. Notably, psoriasis is associated with NAFLD even after adjusting for metabolic syndrome traits and other potential confounding factors. Some studies have also suggested that psoriatic patients are more likely to have the more advanced forms of NAFLD than non-psoriatic controls. The use of drug therapy in patients with a combination of NAFLD and psoriasis with the inclusion of the drug Legalon is pathogenetically justified.

неалкогольная жировая болезнь печенинеалкогольный стеатогепатитпсориазЛегалонnon-alcoholic fatty liver diseasesteatohepatitispsoriasisLegalonReferencesParisi R., Symmons D. P., Griffiths C. E., Ashcroft D. M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013; 133: 377–385.Parisi R., Symmons D. P., Griffiths C. E., Ashcroft D. M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013; 133: 377–385.Griffiths C. E., Barker J. N. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–271.Griffiths C. E., Barker J. N. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–271.Gottlieb A. B., Chao C., Dann F. Psoriasis comorbidities. J. Dermatol. Treat. 2008; 19: 5–21.Gottlieb A. B., Chao C., Dann F. Psoriasis comorbidities. J. Dermatol. Treat. 2008; 19: 5–21.Anstee Q. M., Targher G., Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 330–344.Anstee Q. M., Targher G., Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 330–344.Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig. Liver Dis. 2015, 47, 181–190.Lonardo A., Ballestri S., Marchesini G., Angulo P., Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig. Liver Dis. 2015, 47, 181–190.Byrne C. D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015; 62: S 47–S 64.Byrne C. D., Targher G. NAFLD: A multisystem disease. J. Hepatol. 2015; 62: S 47–S 64.Sommer D. M., Jenisch S., Suchan M., Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298: 321–328.Sommer D. M., Jenisch S., Suchan M., Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2006; 298: 321–328.Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 758–764.Gisondi P., Targher G., Zoppini G., Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 758–764.Miele L., Vallone S., Cefalo C., la Torre G., di Stasi C., Vecchio F. M., D’Agostino M. Gabrieli, M.L., Vero V., Biolato M. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 778–786.Miele L., Vallone S., Cefalo C., la Torre G., di Stasi C., Vecchio F. M., D’Agostino M. Gabrieli, M.L., Vero V., Biolato M. et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51: 778–786.Birkenfeld A. L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713–723.Birkenfeld A. L., Shulman G. I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713–723.Matsumoto T., Suziki N., Watanabe H., Irie M., Iwata K., Anan A., Nakane H., Yoshikane M., Nishizawa S., Sohda T. et al. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 2004; 39: 1102–1110.Matsumoto T., Suziki N., Watanabe H., Irie M., Iwata K., Anan A., Nakane H., Yoshikane M., Nishizawa S., Sohda T. et al. Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J. Gastroenterol. 2004; 39: 1102–1110.Byrne C. D., Targher G., Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: Implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014; 34: 1155–1161.Byrne C. D., Targher G., Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: Implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014; 34: 1155–1161.Hunter C. A., Jones S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015; 16: 448–457.Hunter C. A., Jones S. A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015; 16: 448–457.Shulmann G. I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 2014; 371: 1131–1141.Shulmann G. I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 2014; 371: 1131–1141.Stefan N., Häring H. U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013; 9: 144–152.Stefan N., Häring H. U. The role of hepatokines in metabolism. Nat. Rev. Endocrinol. 2013; 9: 144–152.Gisondi P., Barba E., Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2015; 30: 282–287.Gisondi P., Barba E., Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2015; 30: 282–287.Abedini R., Salehi M., Lajevardi V., Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin. Exp. Dermatol. 2015; 40: 722–727.Abedini R., Salehi M., Lajevardi V., Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin. Exp. Dermatol. 2015; 40: 722–727.Kulkarni N. M., Jaji M. S., Shetty P., Kurhe Y. V., Chaudhary S., Vijaykant G., Raghul J, Vishwakarma S. L., Rajesh B. N., Mookkan J. et al. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. Pharm. Biol. 2015; 53: 1110–1117.Kulkarni N. M., Jaji M. S., Shetty P., Kurhe Y. V., Chaudhary S., Vijaykant G., Raghul J, Vishwakarma S. L., Rajesh B. N., Mookkan J. et al. A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation. Pharm. Biol. 2015; 53: 1110–1117.Nast A., Gisondi P., Ormerod A. D., Saiag P., Smith C., Spuls P.I, Arenberger P., Bachelez H., Barker J., Dauden E. et al. European S 3-Guidelines on the systemic treatment of psoriasis vulgaris — Update 2015—Short version — EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. 2015; 29: 2277–2294.Nast A., Gisondi P., Ormerod A. D., Saiag P., Smith C., Spuls P.I, Arenberger P., Bachelez H., Barker J., Dauden E. et al. European S 3-Guidelines on the systemic treatment of psoriasis vulgaris — Update 2015—Short version — EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. 2015; 29: 2277–2294.Kalb R. E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis: 2009 National psoriasis foundation consensus conference. J. Am. Acad. Dermatol. 2009; 60: 824–837.Kalb R. E., Strober B., Weinstein G., Lebwohl M. Methotrexate and psoriasis: 2009 National psoriasis foundation consensus conference. J. Am. Acad. Dermatol. 2009; 60: 824–837.Hardwick R. N., Clarke J. D., Lake A. D., Canet M. J., Anumol T., Street S. M., Merrell M. D., Goedken M. J., Snyder S. A., Cherrington N. J. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol. Sci. 2014; 142: 45–55.Hardwick R. N., Clarke J. D., Lake A. D., Canet M. J., Anumol T., Street S. M., Merrell M. D., Goedken M. J., Snyder S. A., Cherrington N. J. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol. Sci. 2014; 142: 45–55.Tan K. W., Griffiths C. E. Novel systemic therapies for the treatment of psoriasis. Expert. Opin. Pharmacother. 2016; 17: 79–92.Tan K. W., Griffiths C. E. Novel systemic therapies for the treatment of psoriasis. Expert. Opin. Pharmacother. 2016; 17: 79–92.Dunn L. K., Gaar L. R., Yentzer B. A., O’Neill J.L., Feldman S. R. Acitretin in dermatology: A review. J. Drugs Dermatol. 2011; 10: 772–782.Dunn L. K., Gaar L. R., Yentzer B. A., O’Neill J.L., Feldman S. R. Acitretin in dermatology: A review. J. Drugs Dermatol. 2011; 10: 772–782.Lestre S., Diamantino F., Veloso L, Fidalgo A., Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: A retrospective cohort study. Eur. J. Dermatol. 2011; 21: 916–920.Lestre S., Diamantino F., Veloso L, Fidalgo A., Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: A retrospective cohort study. Eur. J. Dermatol. 2011; 21: 916–920.Gisondi P., Conti A., Galdo G., Piaserico S., de Simone C., Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study. Br. J. Dermatol. 2013; 168: 1124–1127.Gisondi P., Conti A., Galdo G., Piaserico S., de Simone C., Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study. Br. J. Dermatol. 2013; 168: 1124–1127.Campanati A., Ganzetti G., di Sario A., Damiani A., Sandroni L., Rosa L., Benedetti A., Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J. Gastroenterol. 2013; 48: 839–846.Campanati A., Ganzetti G., di Sario A., Damiani A., Sandroni L., Rosa L., Benedetti A., Offidani A. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J. Gastroenterol. 2013; 48: 839–846.Feagins L. A., Flores A., Arriens C., Park C., Crook T., Reimold A., Brown G. Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy. Eur. J. Gastroenterol. Hepatol. 2015; 27: 1154–1160.Feagins L. A., Flores A., Arriens C., Park C., Crook T., Reimold A., Brown G. Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy. Eur. J. Gastroenterol. Hepatol. 2015; 27: 1154–1160.Jensen P., Zachariae C., Christensen R., Geiker N. R., Schaadt B. K., Stender S., Hansen P. R., Astrup A., Skov L. Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatol. 2013; 149: 795–801.Jensen P., Zachariae C., Christensen R., Geiker N. R., Schaadt B. K., Stender S., Hansen P. R., Astrup A., Skov L. Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatol. 2013; 149: 795–801.Gisondi P., del Giglio M., di Francesco V., Zamboni M., Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr. 2008; 88: 1242–1247.Gisondi P., del Giglio M., di Francesco V., Zamboni M., Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am. J. Clin. Nutr. 2008; 88: 1242–1247.Al-Mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin. Biol. Ther. 2014; 14: 749–756.Al-Mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin. Biol. Ther. 2014; 14: 749–756.Vahabzadeh M., Amiri N., Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric. 2018; 98 (13): 4816–4823.Vahabzadeh M., Amiri N., Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric. 2018; 98 (13): 4816–4823.Alkatib S. M., Ismail M. K., AlMoula A.H., Alkennany I. R. Hepatoprotective role of Legalon 70 against hydrogen peroxide in chickens. Int J Health Sci (Qassim). 2019; 13 (4):17–21.Alkatib S. M., Ismail M. K., AlMoula A.H., Alkennany I. R. Hepatoprotective role of Legalon 70 against hydrogen peroxide in chickens. Int J Health Sci (Qassim). 2019; 13 (4):17–21.Hadi A., Pourmasoumi M., Mohammadi H., Symonds M., Miraghajani M. The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med. 2018; 41: 311–319.Hadi A., Pourmasoumi M., Mohammadi H., Symonds M., Miraghajani M. The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med. 2018; 41: 311–319.Ou Q., Weng Y., Wang S., Zhao Y., Zhang F., Zhou J., Wu X. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway. Dig Dis Sci. 2018; 63 (12): 3398–3408.Ou Q., Weng Y., Wang S., Zhao Y., Zhang F., Zhou J., Wu X. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway. Dig Dis Sci. 2018; 63 (12): 3398–3408.Perumpail B. J., Li A. A., Iqbal U., Sallam S., Shah N. D., Kwong W., Cholankeril G., Kim D., Ahmed A. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases. 2018; 6 (3): 80.Perumpail B. J., Li A. A., Iqbal U., Sallam S., Shah N. D., Kwong W., Cholankeril G., Kim D., Ahmed A. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases. 2018; 6 (3): 80.Taleb A., Ahmad K. A., Ihsan A. U., Qu J., Lin N., Hezam K., Koju N., Hui L., Qilong D. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother. 2018; 102: 689–698.Taleb A., Ahmad K. A., Ihsan A. U., Qu J., Lin N., Hezam K., Koju N., Hui L., Qilong D. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother. 2018; 102: 689–698.Vostálová J., Tinková E., Biedermann D., Kosina P., Ulrichová J., Rajnochová Svobodová A. Skin Protective Activity of Silymarin and its Flavonolignans. Molecules. 2019; 24 (6): 1022.Vostálová J., Tinková E., Biedermann D., Kosina P., Ulrichová J., Rajnochová Svobodová A. Skin Protective Activity of Silymarin and its Flavonolignans. Molecules. 2019; 24 (6): 1022.Chu C., Li D., Zhang S., Ikejima T., Jia Y., Wang D., Xu F. Role of silibinin in the management of diabetes mellitus and its complications. Arch Pharm Res. 2018; 41 (8): 785–796.Chu C., Li D., Zhang S., Ikejima T., Jia Y., Wang D., Xu F. Role of silibinin in the management of diabetes mellitus and its complications. Arch Pharm Res. 2018; 41 (8): 785–796.Castera L., Vilgrain, V., Angulo P. Noninvasive evaluation of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 666–675.Castera L., Vilgrain, V., Angulo P. Noninvasive evaluation of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 666–675.Ballestri S., Romagnoli D., Nascimbeni F., Francica G., Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev. Gastroenterol. Hepatol. 2015; 9: 603–627.Ballestri S., Romagnoli D., Nascimbeni F., Francica G., Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev. Gastroenterol. Hepatol. 2015; 9: 603–627.Lonardo A., Ballestri S., Targher G., Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 629–650.Lonardo A., Ballestri S., Targher G., Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 629–650.

The authors declare that there are no conflicts of interest present.